If approved, the legislation would help to speed up review times, address a backlog of applications, mitigate drug shortages and quicken approval of treatments for life-threatening conditions.
These efforts would be supported by several billion dollars in new fees paid by device and drug companies to regulators through 2017. Device makers negotiated their proposed new fees with the FDA in February, while drugmakers reached their agreement in September.
A final vote on passage of the legislation in the Senate may happen this week, and the House of Representatives plans to take up its bill the week of May 28, according to the report.
Related Articles on Medical Devices:
FCC Proposes to Allocate Spectrum for Wireless Medical Devices
Boston Scientific Receives FDA Approval for Epic Vascular Stent
Department of Homeland Security Warns of Mobile Medical Device Security Risks
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
